HCP
CELG

Holt Capital Partners’s Celgene Corp CELG Stock Holding History

Holt Capital Partners’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-400
Closed -$40K – 224
2016
Q1 		$40K Buy
+400
New +$41.2K 0.02% 200

Other funds holding CELG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Holt Capital Partners's CELG Position: Q2 2016 in Review

Holt Capital Partners sold out of Celgene Corp (CELG) in Q2 2016, closing a stake of 400 shares — an estimated $40K sold.

Holt Capital Partners first reported a position in CELG in Q1 2016 and held it in 1 quarter. The position peaked at $40K in Q1 2016. 1,218 funds tracked by Wall St. Rank hold CELG as of Q2 2016.

  • Holt Capital Partners reported no remaining Celgene Corp position as of Q2 2016 after selling out during the quarter.
  • Holt Capital Partners sold 400 Celgene Corp shares in Q2 2016, an estimated $40K.
  • Holt Capital Partners first reported a position in Celgene Corp in Q1 2016 and held it in 1 quarter.
  • Holt Capital Partners's Celgene Corp position peaked at $40K in Q1 2016.
  • 1,218 funds tracked by Wall St. Rank held Celgene Corp as of Q2 2016.

Based on Holt Capital Partners's 13F filing for Q2 2016, filed 15 Aug 2016.